Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Monitoring is most useful when it follows trends in symptoms, congestion, rhythm burden, function, and treatment continuity, rather than reacting to a single visit.
- NT-proBNP and troponin support follow-up, but small changes are hard to interpret outside clinical context.
- Repeat imaging is most informative when symptoms, biomarkers, and examination don't align and when read as a comparison over time.
- Treatment continuity belongs in monitoring because adherence and access gaps can mimic nonresponse.
The Goal of Monitoring in ATTR-CM
The goal of monitoring is to judge whether the disease is stable, progressing, or becoming harder to manage by following clinical trends over time, not by chasing a single decisive marker. Serial review of symptoms, congestion, rhythm burden, functional capacity, blood pressure reserve, and the overall trajectory of the cardiomyopathy provides the most clinically informative monitoring approach. This longitudinal perspective supports coherent clinical assessment across visits.
Interpreting NT-proBNP and Troponin in Follow-Up
NT-proBNP and cardiac troponin are best used as trend-based reference points, not as verdicts. They can support interpretation of myocardial stress and injury, but renal dysfunction, volume shifts, arrhythmia, intercurrent illness, and background heart failure burden can all move the numbers without signaling a true change in amyloid disease. A single value carries far less weight than a consistent direction of travel, and small fluctuations are often noise rather than signal. Reading these markers alongside symptoms and function while considering treatment tolerability separately keeps follow-up grounded.
When Repeat Imaging Changes Interpretation
Repeat imaging is most useful when a specific structural or functional question needs to be resolved, particularly when symptoms, biomarkers, and examination are not aligned and a structural question needs resolving—for example, distinguishing genuine progression from a competing cause of decline. When repeat imaging is performed, comparison with a prior baseline can add useful longitudinal context. In advanced disease, accurate interpretation is particularly important because physiological reserve is limited and clinical decisions carry greater consequence.
Why Treatment Continuity Belongs in Monitoring
Treatment continuity belongs in monitoring because apparent nonresponse can sometimes reflect interrupted treatment exposure rather than disease progression alone. Real-world ATTR-CM care can be disrupted by adherence gaps, refill interruptions, access barriers, and fragmented follow-up, so a checklist of biomarkers is incomplete without a check on whether the patient has actually remained on therapy. Confirming continuity before escalating decisions helps avoid misattributing an exposure problem to inadequate treatment response, and it sets up the longer-term reading of prognostic indicators that accumulate over time.
Practical Monitoring Checklist
At each follow-up, read the trend rather than the snapshot:
- Are symptoms, functional capacity, and congestion moving consistently in one direction over recent visits?
- Do biomarker changes track with the clinical picture, or could renal, volume, rhythm, or intercurrent factors explain them?
- Is there a genuine misalignment that a repeat imaging study, compared to baseline, would actually resolve?
- Has the patient remained continuously on therapy, or were there refill, access, or tolerability interruptions?
- Before escalating, has underexposure been excluded as an explanation for apparent nonresponse?
Clinical Decision Point
When a follow-up assessment suggests clinical deterioration, the decision is not whether one marker has crossed a threshold, but whether the overall trajectory has changed and whether treatment continuity has been maintained. A single abnormal value invites repeat assessment and context; a consistent downward trend, with exposure confirmed, should prompt reassessment of the treatment plan.
Frequently Asked Questions
What’s the main goal of follow-up in ATTR-CM?
The goal is to judge whether the disease is stable, progressing, or becoming harder to manage by following clinical and functional trends over time, rather than reacting to any single visit or value.
How should NT-proBNP and troponin be interpreted?
They should be read as useful trend markers rather than stand-alone answers. Renal dysfunction, volume status, arrhythmia, and intercurrent illness can all confound small changes, so a direction over several measurements is more meaningful than one result.
When is repeat imaging worth doing?
Repeat imaging is mainly worth doing when symptoms, biomarkers, and examination disagree and a structural question needs resolving. Imaging is most informative as a comparison against a prior baseline, not as an isolated study.
Why does adherence belong in monitoring?
Adherence belongs in monitoring because interruptions in therapy or follow-up can make apparent treatment failure harder to interpret. Confirming continuous exposure before escalating prevents mistaking underexposure for genuine nonresponse.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Manage the Disease
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Baseline Characteristics and Secondary Medication Adherence Among Medicare Patients Diagnosed with ATTR-CM and/or Receiving Tafamidis Prescriptions. Journal of Managed Care & Specialty Pharmacy
- Monitoring Disease Progression in Patients With Transthyretin Amyloid Cardiomyopathy. JACC Heart Failure
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.